TScan cuts 75% of workforce while shifting focus to solid tumor program
TScan cuts 75% of workforce while shifting focus to solid tumor program
TScan Therapeutics
TScan Therapeutics is a clinical-stage immunotherapy company developing a portfolio of TCR-T cell therapies for hematologic malignancies and solid tumors. The company's lead program TSC-101 is in the ALLOHA Phase 1 study for patients with hematologic malignancies undergoing allogeneic hematopoietic cell transplantation, with positive initial data from Cohort C reported in 2026 showing 11 of 14 dosed patients achieving complete donor chimerism. TScan is preparing TSC-101 for a planned Phase 3 study in blood cancers as the next value-driving event. The company has also established a Cellares automated-manufacturing agreement for TSC-101 production scalability. TScan is headquartered in Waltham, Massachusetts and trades on the Nasdaq Capital Market under the symbol TCRX.
Company Info
Sector:Biotechnology / Cell Therapy (TCR-T Engineered T Cells)
Headquarters:Waltham, Massachusetts, USA
Founded:2018
Website:www.tscan.com/
Upcoming Milestones & Key Dates
Late Q3 2026
Clinical Data
Next data cut from the ALLOHA Phase 1 study of TSC-101
Q2 2026
Corporate
Q2 2026 financial results and pipeline update
Clinical Development Pipeline
TSC-101
Target: TCR-T cell therapy directed against minor histocompatibility antigens (HA-1, HA-2)Solid tumor TCR-T pipeline
Target: TCR-T cell therapy platformWorkforce & Restructuring Tracker
View Industry Layoff Tracker →96 roles (75%)WARN Notice
TScan Therapeutics slashed 75% of its workforce (96 employees per Massachusetts WARN filings) and parted ways with its CFO and CMO, pausing its Phase 3 ALLOHA-2 hematologic malignancy program to focus on TCR-T solid tumor and in vivo candidates.
Recent News
Leadership Team
Gavin MacBeath, Ph.D.
Chief Executive Officer